PDF Download

ACIDO EPSILON AMINOCAPROICO PDF

J. 47, () Gibelli, A.: Richerche sull’azione antifibrinolitica dell’acido epsilon-amino-caproico. III. Lazione dell’acido epsilon-aminocaproico quale. Ácido aminocapróico. acidum aminocaproicum. Aminocaproic Acid; Aminocapronsäure. EACA; EACS; Epsilcapramine; Epsilon Aminocaproic Acid. gramento, coagulopatia e necessidade de derivados de sangue. Os agentes farmacológicos aprotinina, ácido epsilon-aminocapróico e ácido tranexâmico são.

Author: JoJonos Dam
Country: Colombia
Language: English (Spanish)
Genre: Art
Published (Last): 1 October 2014
Pages: 165
PDF File Size: 6.73 Mb
ePub File Size: 17.68 Mb
ISBN: 452-9-59703-976-2
Downloads: 15838
Price: Free* [*Free Regsitration Required]
Uploader: Yozshule

An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein aa risk factor for vascular disease. Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin.

With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein a have been shown to increase the risk epsiloon vascular disease. Lipoprotein 9a a has two components, apolipoprotein B, linked to apolipoprotein a. Aminocaproic acid may change the conformation of apoliprotein achanging ajinocaproico binding properties and potentially preventing the formation of lipoprotein a. Absorbed rapidly following oral aminocaporico.

In adults, oral absorption appears to be a zero-order process with an absorption rate of 5. The mean lag time in absorption is 10 minutes. Renal excretion is the primary route of elimination, whether aminocaproic acid is administered orally or intravenously. A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to amunocaproico.

The intravenous and oral LD 50 were 3. An intravenous infusion dose of epsilkn. Frantisek Mares, “Process for producing caprolactam from 6-aminocaproic acid.

Patent US, issued August, Drug created on June 13, Aminocaproic Acid Targets 3 Enzymes 1 Biointeractions 3. Drug Interaction Alphaproteinase inhibitor Alphaproteinase inhibitor may increase the thrombogenic activities of Aminocaproic Acid. Aminomethylbenzoic acid Aminocaproic Acid may increase the thrombogenic activities of Aminomethylbenzoic acid. Andexanet alfa Aminocaproic Acid may increase rpsilon thrombogenic activities of Andexanet alfa.

  BORN ON THE FOURTH OF JULY RON KOVIC PDF

Anti-inhibitor coagulant complex Aminocaproic Acid may increase the thrombogenic activities of Anti-inhibitor coagulant complex. Antihemophilic factor human Aminocaproic Acid may increase the thrombogenic activities of Aminocaprpico factor human.

Antihemophilic factor, human recombinant Aminocaproic Acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.

Aprotinin Aminocaproic Acid may increase the thrombogenic activities of Aprotinin. Beroctocog alfa Aminocaproic Acid may increase the thrombogenic activities of Beroctocog alfa.

Calcium aicdo Aminocaproic Acid may increase the thrombogenic activities of Calcium cation. Calcium threonate Aminocaproic Acid may increase the thrombogenic activities of Calcium threonate. Camostat Aminocaproic Acid may increase the thrombogenic activities of Camostat. Coagulation factor X human Aminocaproic Acid may increase the thrombogenic activities of Coagulation factor X caido.

Damoctocog alfa pegol Aminocaproic Acid may increase the thrombogenic activities of Damoctocog alfa pegol. Emicizumab Aminocaproic Acid may increase the thrombogenic activities of Emicizumab. Fibrinogen Human The therapeutic efficacy of Fibrinogen Human can be increased when used in combination with Aminocaproic Acid. Hydrogen peroxide Aminocaproic Acid may increase the thrombogenic activities of Hydrogen peroxide.

Kallidinogenase Aminocaproic Acid may increase the thrombogenic activities of Kallidinogenase. Menadione Menadione may increase the thrombogenic activities of Aminocaproic Acid. Moroctocog alfa Aminocaproic Acid may increase the thrombogenic activities of Moroctocog alfa.

Nonacog beta pegol Aminocaproic Acid may increase the thrombogenic activities of Nonacog beta pegol. Pantothenic acid Aminocaproic Acid may increase the thrombogenic activities of Pantothenic acid. Phylloquinone Aminocaproic Acid may increase the thrombogenic activities of Phylloquinone. Prothrombin Aminocaproic Acid may increase the thrombogenic activities of Prothrombin. Rusalatide acetate Aminocaproic Acid may increase the thrombogenic activities of Rusalatide acetate.

Susoctocog alfa Aminocaproic Acid may increase the thrombogenic activities of Susoctocog alfa. Tranexamic acid Tranexamic Acid aminocaprokco increase zcido thrombogenic activities of Aminocaproic Acid. Trenonacog alfa Aminocaproic Acid may increase the thrombogenic activities of Trenonacog alfa. Tretinoin The risk or severity of Thrombosis can be increased when Tretinoin is combined with Aminocaproic Acid.

Turoctocog alfa Aminocaproic Acid may increase the thrombogenic activities of Turoctocog alfa.

Aminocaproic acid

Vatreptacog alfa Aminocaproic Acid may increase the thrombogenic activities of Vatreptacog alfa. Xanodyne pharmaceutics inc Abraxis pharmaceutical products Baxter healthcare corp anesthesia and critical care Hospira inc Luitpold pharmaceuticals inc Mikart inc. DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Aminocaproic Acid – DrugBank

General Function Serine-type peptidase activity Specific Function Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. Recombinant kringle IV modules of human apolipoprotein a: Impaired activation of the fibrinolytic system in children with Henoch-Schonlein purpura: Effect of a synthetic carboxy-terminal peptide of alpha 2 -antiplasmin qcido urokinase-induced fibrinolysis.

  DENON UD-M50 SERVICE MANUAL PDF

The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Analysis of plasmin binding and urokinase activation of plasminogen bound to mainocaproico Heymann nephritis autoantigen, gp General Function Serine-type endopeptidase activity Specific Function Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen.

By controlling plasmin-mediated proteolysis, it plays an important role in t Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. Human Co colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.

Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis. General Function Serine-type endopeptidase activity Specific Function Apo a is the main constituent of lipoprotein a Lp a.

It has serine proteinase activity and is able of autoproteolysis.

Inhibits tissue-type plasminogen activator 1. Lp a may be a ligand for m How many drug targets are there? Nat Rev Drug Discov. Drugs, their targets and the nature and number of drug targets. Identification of sequences in apolipoprotein a that maintain its closed conformation: General Function Xanthine dehydrogenase activity Specific Function Oxidase with broad substrate epsilom, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal A cyclic imine intermediate in the in vitro metabolic conversion of 1,6-diaminohexane to 6-aminohexanoic acid and caprolactam.

A Tissue-type plasminogen activator. Aminocaproic Acid Action Pathway. Aminocaproic Acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.

The therapeutic efficacy of Fibrinogen Human can be increased when used in combination with Aminocaproic Acid. The risk or severity of Thrombosis can be increased when Tretinoin is combined with Aminocaproic Acid.